European Expert Recommendations on Teclistamab Management for Relapsed or Refractory Multiple Myeloma.


Por: Rodríguez-Otero P, Moreau P, Mateos MV, Krauth MT, Rasche L, Kastritis E, Oriol A, Zamagni E, Albrecht C, Rubio-Azpeitia E and van de Donk NWCJ

Publicada: 1 mar 2026 Ahead of Print: 13 dic 2025
Resumen:
The global incidence of multiple myeloma (MM) continues to rise. While survival rates for newly diagnosed patients have improved substantially with the introduction of novel therapies, outcomes remain poor for those with triple-class-exposed (TCE) relapsed/refractory MM (RRMM). Recent therapeutic innovations, including chimeric antigen receptor T-cell therapy, antibody-drug conjugates, and bispecific antibodies, offer new effective options for this challenging population. Teclistamab, the first approved B-cell maturation antigen-targeted bispecific antibody, has demonstrated deep and durable responses and an acceptable safety profile in TCE RRMM. Teclistamab is now a recommended treatment from second relapse onwards in patients with TCE RRMM in the 2025 European Hematology Association-European Myeloma Network guidelines. Nevertheless, considering the novelty of this agent and its overall safety profile, there is a need for clear guidance on patient management in routine clinical practice. Here, we aim to provide a comprehensive overview of the clinical profile of teclistamab and expert recommendations on its optimal use in TCE RRMM. We focus on key aspects and considerations needed for patient selection (including special populations such as the elderly, frail individuals, those with extramedullary disease or renal impairment), as well as therapy initiation, and strategies for adverse event prevention, monitoring, and management. Ultimately, this review aims to support physicians in maximizing the therapeutic potential of teclistamab, improving outcomes for patients through tailored, evidence-based management.

Filiaciones:
Rodríguez-Otero P:
 Cancer Center Clínica Universidad de Navarra, CCUN, CIMA, CIBERONC, IDISNA, Pamplona, Spain

Moreau P:
 Centre Hospitalier Universitaire de Nantes, Nantes, France

Mateos MV:
 University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca, Spain

Krauth MT:
 Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria

Rasche L:
 Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany

Kastritis E:
 Department of Clinical Therapeutics, School of Medicine, "Alexandra" General Hospital, National and Kapodistrian University of Athens, Athens, Greece

:
 Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain

Zamagni E:
 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy

 Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy

Albrecht C:
 Johnson & Johnson, Issy les Moulineaux, France

Rubio-Azpeitia E:
 Johnson & Johnson, Madrid, Spain

van de Donk NWCJ:
 Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
ISSN: 21522650





Clinical Lymphoma Myeloma & Leukemia
Editorial
Cancer Media Group, 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 26 Número: 3
Páginas: 408-420
WOS Id: 001708166800001
ID de PubMed: 41577552
imagen hybrid

MÉTRICAS